CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
Pittsburgh, Pennsylvania, United States and 42 other locations
combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 26 other locations
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy t...
Phase 2
Pittsburgh, Pennsylvania, United States and 1 other location
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 67 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Pittsburgh, Pennsylvania, United States and 138 other locations
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trast...
Phase 3
Pittsburgh, Pennsylvania, United States and 191 other locations
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...
Phase 3
Pittsburgh, Pennsylvania, United States and 176 other locations
GEJ adenocarcinoma in adult participants.The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to place...
Phase 3
Pittsburgh, Pennsylvania, United States and 214 other locations
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...
Phase 3
Pittsburgh, Pennsylvania, United States and 199 other locations
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immuno...
Phase 1
Pittsburgh, Pennsylvania, United States and 5 other locations
Clinical trials
Research sites
Resources
Legal